文献速递脑血管病外科神经重症

早期克拉生坦加重SAH后神经源性肺水肿而延迟给药安全

Detrimental Effect of Early Clazosentan Administration on Neurogenic Pulmonary Edema Following Subarachnoid Hemorrhage and Safety of Its Delayed Administration: Laboratory Investigation.
PubMed 文献 · World Neurosurg · 2025-12-13

该小鼠实验通过血管内穿孔诱导蛛网膜下腔出血(SAH),早期(SAH后3小时)给予克拉生坦10 mg/kg,24小时后肺含水量及肺损伤病理评分显著高于溶剂对照组(P<0.05);延迟(SAH后1天)给药并在2天后评估,则未见显著差异。结论提示早期克拉生坦加重SAH诱导的神经源性肺水肿(NPE),延迟给药无此不利效应。

要点

  • 早期(SAH后3小时)克拉生坦10 mg/kg加重小鼠SAH后神经源性肺水肿。
  • 延迟(SAH后1天)克拉生坦给药未显示对肺水肿的不利效应。
  • NPE改善后,克拉生坦或可安全用于SAH患者。

核心结论

  • 早期给予克拉生坦加重SAH诱导的神经源性肺水肿,延迟给药未表现此不利效应。

研究设计与样本

  • 雄性小鼠血管内穿孔诱导SAH,早期组SAH后3小时给克拉生坦10 mg/kg或生理盐水、24小时评估;延迟组SAH后1天给药、2天评估。

主要发现

  • 早期给药实验中,SAH+克拉生坦组肺含水量显著高于SAH+溶剂组(P<0.05)。
  • 早期给药实验中,SAH+克拉生坦组肺损伤病理评分显著高于SAH+溶剂组(P<0.05)。
  • 延迟给药实验中,各组间肺含水量及病理评分未见显著差异。

临床怎么用

  • 对SAH后出现神经源性肺水肿的患者,应避免早期使用克拉生坦,待NPE改善后可考虑延迟给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clazosentan, an endothelin A receptor antagonist, has been used to prevent cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH). It is unclear whether clazosentan is safe for patients presenting neurogenic pulmonary edema (NPE) because pulmonary edema is a well-known side effect of clazosentan. This study aimed to evaluate the effects of clazosentan on SAH-induced NPE. METHODS: SAH was induced by endovascular perforation in male mice. Clazosentan (10 mg/kg) or saline was administered 3 hours after SAH onset (early administration). The mice were euthanized 24 hours after onset, and wet/dry ratios of the excised brain, lung, liver, and kidney were measured. Histopathological images of each tissue were evaluated. Furthermore, similar evaluations were performed in mice that received clazosentan one day after onset (delayed administration) and were euthanized two days after onset. RESULTS: In the experiment with early clazosentan administration, the lung water content in the SAH+clazosentan group was significantly higher than that in the SAH+vehicle group (P<0.05). The histopathological score for lung injury in the SAH+clazosentan group was significantly higher than that in the SAH+vehicle group (P<0.05). In the experiment with delayed clazosentan administration, no significant differences in lung water contents and histopathological scores were observed between the groups. CONCLUSIONS: While the early administration of clazosentan exacerbated SAH-induced NPE, delayed administration did not exhibit this detrimental effect. Clazosentan may safely be utilized in clinical settings for patients with SAH who develop NPE, provided that NPE shows improvement.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Sasaki N, Egashira Y, Sasaibe S, et al. Detrimental Effect of Early Clazosentan Administration on Neurogenic Pulmonary Edema Following Subarachnoid Hemorrhage and Safety of Its Delayed Administration: Laboratory Investigation. World Neurosurg. 2025. PMID: 41391600. doi:10.1016/j.wneu.2025.124721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。